Syngene International’s shares surged nearly 17% to Rs 505.60 on Thursday, even as the Bengaluru-based CRDMO reported a 19% year-on-year drop in Q4 net profit to Rs 148 crore, the company said in its BSE filing. Revenue for the quarter rose 2% year-on-year to Rs 1,037 crore and jumped 13% sequentially from Rs 917 crore in Q3 FY26. The stock was down 23% in calendar 2026 heading into results, beaten down enough that one clean sequential quarter was enough to trigger a sharp relief rally.
One Biologics Client Dragged the Whole Year—The Q3 PAT of Rs 15 Crore Says It All
The scale of the single-client damage is best understood through one number: Syngene’s Q3 FY26 net profit was Rs 15 crore. Thursday’s reported PAT of Rs 148 crore is a near tenfold sequential jump, not a business recovery, but a base effect from the worst quarter of the biologics inventory correction. The Q4 PAT figure also includes two exceptional line items: a Rs 20 crore gratuity re-measurement credit arising from revised labour codes, and a Rs 25 crore exceptional loss booked on employee termination benefits under approved policy. Profit after tax before exceptional items was Rs 153 crore in Q4, down 16% year-on-year.
For the full year, operating EBITDA fell 12% to Rs 918 crore, pulling FY26 margins to 25% from 29% a year ago. CFO Deepak Jain said the numbers reflect “the ongoing product impact in our largest biologics customer,” a single large-molecule client whose inventory correction has run through four consecutive quarters. The biologics client has not been publicly named by Syngene. The 13% sequential revenue recovery in Q4, however, is the clearest signal yet that the correction is running its course revenues had been Rs 777 crore in Q1, Rs 910 crore in Q2, and Rs 917 crore in Q3 and are now back above Rs 1,000 crore.
Macquarie Outperform, Rs 835 Target: EBITDA Beat, PAT Miss
Macquarie maintained its Outperform rating on Syngene with a target price of Rs 835, according to CNBC-TV18, implying over 93% upside from the pre-results close of Rs 432.15. The brokerage said Q4 EBITDA came in 11% ahead of its estimates, while adjusted net profit at Rs 150 crore was 8% below expectations. Those are the exceptional items doing the work; operationally, the quarter was ahead of the Street. Broader analyst consensus had a 12-month target of Rs 947–1,108 on the stock, making Macquarie’s Rs 835 the most conservative number in the pack.
ADCs, BMS to 2035, and a New CEO: What the Market Is Pricing In
During Q4, Syngene commissioned a new ADC discovery laboratory for high-throughput handling of potent compounds, completing an end-to-end platform from discovery to GMP manufacturing, placing it among a handful of Indian CRDMOs with full-service antibody-drug conjugate capability. The timing matters: the global ADC contract manufacturing market was valued at $8.87 billion in 2024 and is projected to reach $16.55 billion by 2030, growing at a CAGR of 11%, according to Grand View Research. Syngene is now positioned to capture that outsourcing wave directly.
In Q3, Syngene extended its relationship with Bristol Myers Squibb through to 2035, a ten-year anchor contract that gives long-term revenue visibility regardless of any single biologics product correction. That detail, buried in Biocon’s quarterly filing, never made it into most results coverage. It should have.
The leadership transition is being read as a continuity signal by analysts tracking the stock. Macquarie’s “Outperform” rating was maintained through the changeover, a sign institutional confidence in management succession is intact. Siddharth Mittal, formerly MD & CEO of Biocon, takes over from Peter Bains on July 1, 2026. Kiran Mazumdar-Shaw, who transitioned to Executive Chairperson effective April 1, said the company is investing in “AI and digital capabilities” to drive speed and productivity, though full-year EBITDA margins still fell 400 basis points to 25% during her first year at the helm in the new role.
Cash Strong, Dividend Modest, Stock Still Deeply in the Red
Syngene generated Rs 521 crore in cash during FY26 post-capex, strengthening its balance sheet through a year where margins fell sharply. The board recommended a final dividend of Rs 1.25 per share, subject to shareholder approval at the 33rd AGM on July 29, 2026. The stock’s one-year return is down 21% and its three-year return down 26%. Thursday’s 17% move recovered a portion of that; the market cap stands at approximately Rs 20,280 crore.
Also Read: SYNGENE INTERNATIONAL Share Price Chart: Live
FAQ
Q: Why did Syngene stock rally 17% when profits fell 19%?
The sequential recovery drove the move. Q4 PAT jumped to Rs 148 crore from just Rs 15 crore in Q3, a near ten-fold increase. EBITDA came in 11% ahead of Macquarie’s estimates, and the 13% sequential revenue recovery signalled the biologics client correction is fading. The stock had also been beaten down 23% in 2026 before the results, leaving room for a sharp relief trade.
Q: What were the exceptional items in Syngene’s Q4 FY26 results?
Two items: a Rs 20 crore gratuity re-measurement credit from revised labour codes, and a Rs 25 crore exceptional loss on employee termination benefits under company policy. Net effect: reported PAT of Rs 148 crore versus core PAT before exceptionals of Rs 153 crore.
Q: Who is Syngene’s new CEO, and when does he take over?
Siddharth Mittal, formerly MD & CEO of Biocon, takes over as Syngene’s MD & CEO from July 1, 2026, for a five-year term. Peter Bains steps down June 30, 2026. The 33rd AGM where the final dividend will be approved is scheduled for July 29, 2026.
